期刊
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
卷 63, 期 18, 页码 1815-1822出版社
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2014.02.529
关键词
acute coronary syndrome; angina; coronary artery disease; endothelium; hypertension; myocardial infarction; pre-eclampsia; vascular function
资金
- Medicines Co.
- Bristol-Myers Squibb/Sanofi-Avents
- Lilly/Daiichi Sankyo
- Regado Biosciences
- STENTYS
- Abbott Vascular
- AstraZeneca
- Boston Scientific
- Covidien
- CSL Behring Janssen (JNJ)
- Maya Medical
- Merck
Cardiovascular disease continues to be the leading cause of death in the western world. Due to advancements in diagnosis, prevention, and treatment, cardiovascular mortality has fallen in recent years. Previous studies have evaluated the impact of traditional risk factors such as hypercholesterolemia and smoking. However, limited studies have been conducted to evaluate sex discrepancies among patients with cardiovascular disease. Pre-eclampsia is a multisystem placentally mediated disease, which usually arises after 32 weeks of gestation and classically presents with hypertension and proteinuria. Pre-eclampsia affects 2% to 8% of all pregnancies worldwide and is often complicated by fetal growth restriction. Women with a history of pre-eclampsia are at increased risk of future cardiovascular complications. Therefore, this topic is of significance to the cardiovascular health of over 300 million women worldwide. The goal of this review is to determine the association of pre-eclampsia and future cardiovascular risk and to explore the potential management options for these high-risk women. (C) 2014 by the American College of Cardiology Foundation
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据